Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Amicus Therapeutics revenue
Amicus Therapeutics's revenue is $528.3 million.
What is Amicus Therapeutics's revenue?
- Amicus Therapeutics's revenue growth from 2014 to 2024 is 43,061.36%.
- Amicus Therapeutics has 508 employees, and the revenue per employee ratio is $1,039,950.
- Amicus Therapeutics's peak quarterly revenue was $149.7M in 2024(q4).
- Amicus Therapeutics peak revenue was $528.3M in 2024.
- Amicus Therapeutics annual revenue for 2023 was 399.4M, 21.3% growth from 2022.
- Amicus Therapeutics annual revenue for 2024 was 528.3M, 32.29% growth from 2023.
On this page
Zippi applies for you, and finds you a job.
Amicus Therapeutics historical revenue
Amicus Therapeutics's peak revenue was $528.3M in 2024. The peak quarterly revenue was $149.7M in 2024(q4).
Amicus Therapeutics's revenue increased from $1.2m in 2014 to $528.3M currently. That's a 43,061.36% change in annual revenue.
Amicus Therapeutics annual revenue
Amicus Therapeutics annual revenue over time
| Fiscal year / year | Amicus Therapeutics revenue |
|---|---|
| 2014 | $1.2M |
| 2016 | $5.0M |
| 2017 | $36.9M |
| 2018 | $91.2M |
| 2019 | $182.2M |
| 2020 | $260.9M |
| 2021 | $305.5M |
| 2022 | $329.2M |
| 2023 | $399.4M |
| 2024 | $528.3M |
How accurately did Amicus Therapeutics' revenue projections match actual performance?
Amicus Therapeutics annual growth
Amicus Therapeutics saw the greatest revenue growth in 2017, when revenue increased by 644.86%.
Amicus Therapeutics had the lowest revenue growth in 2022, when revenue changed by 7.76%.
Amicus Therapeutics annual growth rate over time
| Year | Amicus Therapeutics growth |
|---|---|
| 2016 | 305%↑ |
| 2017 | 645%↑ |
| 2018 | 147%↑ |
| 2019 | 100%↑ |
| 2020 | 43%↑ |
| 2021 | 17%↑ |
| 2022 | 8%↑ |
| 2023 | 21%↑ |
| 2024 | 32%↑ |
Amicus Therapeutics quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Amicus Therapeutics quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2014 | $456,000 | $475,000 | $293,000 | - |
| 2016 | - | - | $2.1M | $2.8M |
| 2017 | $4.2M | $7.2M | $10.9M | $14.7M |
| 2018 | $16.7M | $21.3M | $20.6M | $32.6M |
| 2019 | $34.0M | $44.1M | $48.8M | $55.3M |
| 2020 | $60.5M | $62.4M | $67.4M | $70.6M |
| 2021 | $66.4M | $77.4M | $79.5M | $82.2M |
| 2022 | $78.7M | $80.7M | $81.7M | $88.1M |
| 2023 | $86.3M | $94.5M | $103.5M | $115.1M |
| 2024 | $110.4M | $126.7M | $141.5M | $149.7M |
Amicus Therapeutics jobs nearby
Do you work at Amicus Therapeutics?
Did Amicus Therapeutics meet its revenue projections?
Amicus Therapeutics financial information
| CEO | John Francis Crowley |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 508 |
| Date Founded | 2002 |
| Headquarters | Cranbury, New Jersey |
| Number of Locations | 2 |
| Revenue | $528.3M |
| Net Income | -$236,568,000 |
| Gross Proft | $475.4M (2024) |
| EBITDA | $24.0M (2024) |
| PE Ratio | -37.22 |
| Tax Rate | -1.0% |
| Market Capitalization | $2.1B |
| Total Assets | $724,167,000 |
| Ticker | FOLD |
Amicus Therapeutics jobs you might like
Amicus Therapeutics financing
Amicus Therapeutics received early financing of $2.0M on 2002-07-25.
| Series | Round size | Date |
|---|---|---|
| Series A | $2M | 07/2002 |
| Series B | $31M | 05/2004 |
| Series C | $55M | 09/2005 |
| Series D | $60M | 09/2006 |
| Post Ipo Equity | $18.5M | 03/2010 |
| Post Ipo Equity | $31.3M | 11/2010 |
| Grant | $500K | 12/2010 |
| Grant | $186K | 02/2012 |
| Post Ipo Equity | $18.6M | 07/2012 |
| Post Ipo Equity | $15M | 12/2013 |
| Post Ipo Debt | $10M | 12/2013 |
| Post Ipo Equity | $201M | 06/2019 |
| Post Ipo Debt | $400M | 07/2020 |
Amicus Therapeutics investors
| Investors | Security type |
|---|---|
| CHL Medical Partners | Series A |
| Canaan Partners | Series B |
| CHL Medical Partners | Series B |
| New Enterprise Associates (NEA) | Series B |
| Frazier Healthcare Partners | Series B |
| Prospect Venture Partners | Series B |
| Radius Ventures | Series B |
| Canaan Partners | Series C |
| CHL Medical Partners | Series C |
| New Enterprise Associates (NEA) | Series C |
| Frazier Healthcare Partners | Series C |
| Prospect Venture Partners | Series C |
| Garden State Life Sciences Venture | Series C |
| Quaker Bio Ventures | Series C |
| Palo Alto Investors | Series C |
| Radius Ventures | Series C |
| Canaan Partners | Series D |
| CHL Medical Partners | Series D |
| New Enterprise Associates (NEA) | Series D |
| Frazier Healthcare Partners | Series D |
| Prospect Venture Partners | Series D |
| Palo Alto Investors | Series D |
| Quaker Bio Ventures | Series D |
| Radius Ventures | Series D |
| Michael J. Fox Foundation for Parkinson s Research | Grant |
| Muscular Dystrophy Association | Grant |
| GSK PLC | Post Ipo Equity |
| Oxford Finance LLC | Post Ipo Debt |
| MidCap Financial | Post Ipo Debt |
| Silicon Valley Bank | Post Ipo Debt |
| HAYFIN CAPITAL MANAGEMENT LLP | Post Ipo Debt |
Amicus Therapeutics competitors
Amicus Therapeutics's top competitor, Merck, earned an annual revenue of $64.2B.
Amicus Therapeutics's smallest competitor is Morphotek with revenue of $4.8M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Regeneron | $85,589 | $14.2B | 9,123 | 319 |
| Seagen | $85,008 | $2.0B | 900 | - |
| Gilead Sciences | $99,828 | $28.8B | 11,800 | 760 |
| Sanofi Genzyme | $84,495 | $4.6B | 12,000 | - |
| Amgen | $93,349 | $33.4B | 22,000 | 696 |
| Merck | $90,328 | $64.2B | 74,000 | 2,446 |
| Medivation | $94,135 | $1.0B | 628 | - |
| Ariad Pharmaceuticals | $94,078 | $118.8M | 380 | - |
| Astellas Gene Therapies | $45,841 | $6.0M | 76 | - |
| BioMarin | $87,259 | $2.9B | 2,581 | 79 |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Amicus Therapeutics highest paying jobs
Zippia gives an in-depth look into the details of Amicus Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Amicus Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at Amicus Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Amicus Therapeutics. The data presented on this page does not represent the view of Amicus Therapeutics and its employees or that of Zippia.
Amicus Therapeutics may also be known as or be related to AMICUS THERAPEUTICS INC, Amicus Therapeutics, Amicus Therapeutics Inc, Amicus Therapeutics Inc. and Amicus Therapeutics, Inc.